{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:44:13Z","timestamp":1759412653715},"reference-count":56,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2019.06.023","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T16:56:57Z","timestamp":1561049817000},"page":"4344-4353","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages"],"prefix":"10.1016","volume":"37","author":[{"given":"Paul A.","family":"Tambyah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolene","family":"Oon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosmonaliza","family":"Asli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Kristanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Hsia","family":"Hwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fue","family":"Vang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lovkesh","family":"Karwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilad S.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansi","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subash C.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan T.","family":"Stinchcomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.06.023_b0005","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1473-3099(10)70194-8","article-title":"Virology, epidemiology, pathogenesis, and control of enterovirus 71","volume":"10","author":"Solomon","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.023_b0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/1471-2334-13-539","article-title":"Epidemiology and clinical characteristics of hand foot, and mouth disease in a Shenzhen sentinel hospital from 2009 to 2011","volume":"13","author":"Wang","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.023_b0015","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJM199909233411302","article-title":"Neurologic complications in children with enterovirus 71 infection","volume":"341","author":"Huang","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.06.023_b0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(98)24031-1","article-title":"Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease","volume":"352","author":"Chang","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2019.06.023_b0025","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/jech-2014-203836","article-title":"Enterovirus 71 related severe hand, foot and mouth disease outbreaks in South-East Asia: current situation and ongoing challenges","volume":"68","author":"Sabanathan","year":"2014","journal-title":"J Epidemiol Community Health"},{"issue":"13","key":"10.1016\/j.vaccine.2019.06.023_b0030","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJM199909233411301","article-title":"An epidemic of enterovirus 71 infection in Taiwan","volume":"341","author":"Ho","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.06.023_b0035","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s11434-015-0847-3","article-title":"Achievements, challenges and prospects for the development of broadly protective multivalent vaccines and therapeutic antibodies against hand, foot and mouth disease","volume":"60","author":"Lyu","year":"2015","journal-title":"Sci Bull"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.023_b0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000442","article-title":"Severity and burden of hand, foot and mouth disease in Asia: a modelling study","volume":"3","author":"Koh","year":"2018","journal-title":"BMJ Glob Health"},{"issue":"6","key":"10.1016\/j.vaccine.2019.06.023_b0045","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/21645515.2018.1442997","article-title":"Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation","volume":"14","author":"Hu","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.06.023_b0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.meegid.2009.05.010","article-title":"Phylogenetic designation of enterovirus 71 genotypes and sub-genotypes using complete genome sequences","volume":"10","author":"Chan","year":"2009","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.vaccine.2019.06.023_b0055","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1586\/erv.09.152","article-title":"Development of enterovirus 71 vaccines","volume":"9","author":"Lee","year":"2010","journal-title":"Exp Rev Vacc"},{"issue":"7","key":"10.1016\/j.vaccine.2019.06.023_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003044","article-title":"Monitoring antigenic variations of enterovirus 71: implications for virus surveillance and vaccine development","volume":"8","author":"Chia","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2019.06.023_b0065","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/JCM.00630-09","article-title":"Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008","volume":"47","author":"Huang","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.06.023_b0070","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.4161\/hv.21739","article-title":"Production of EV71 vaccine candidates","volume":"8","author":"Chong","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.06.023_b0075","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.vaccine.2010.08.080","article-title":"Combined peptides of human enterovirus 71 protect against virus infection in mice","volume":"28","author":"Liu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.023_b0080","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.vaccine.2005.12.047","article-title":"Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71","volume":"24","author":"Chen","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.023_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021757","article-title":"Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice","volume":"6","author":"Meng","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.06.023_b0090","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.vaccine.2008.01.058","article-title":"Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge","volume":"26","author":"Chung","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.023_b0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1479-0556-5-6","article-title":"DNA vaccine constructs against enterovirus 71 elicit immune response in mice","volume":"5","author":"Tung","year":"2007","journal-title":"Genet Vaccines Ther"},{"key":"10.1016\/j.vaccine.2019.06.023_b0100","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1128\/JVI.02856-06","article-title":"An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys","volume":"81","author":"Arita","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.06.023_b0105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/JVI.00999-09","article-title":"Formaldehyde-inactivated whole virus vaccine protects a murine model of Enterovirus 71 encephalomyelitis against disease","volume":"84","author":"Ong","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.06.023_b0110","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.vaccine.2012.03.010","article-title":"Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial","volume":"30","author":"Li","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.023_b0115","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(13)61049-1","article-title":"Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.06.023_b0120","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.vaccine.2013.03.015","article-title":"A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine","volume":"31","author":"Cheng","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.06.023_b0125","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/21645515.2015.1115934","article-title":"Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2019.06.023_b0130","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2019.06.023_b0135","article-title":"EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases","volume":"5","author":"Mao","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2019.06.023_b0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.virol.2017.03.017","article-title":"Impact of genetic changes, pathogenicity and antigenicity on enterovirus- A71 vaccine development","volume":"506","author":"Yee","year":"2017","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2019.06.023_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079783","article-title":"Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against sub-genotypes B1, B4, B5 and C4A in adult volunteers","volume":"8","author":"Chou","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.06.023_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002538","article-title":"Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine","volume":"7","author":"Hwa","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.06.023_b0155","unstructured":"http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074775.htm [Accessed March 13, 2014]."},{"key":"10.1016\/j.vaccine.2019.06.023_b0160","unstructured":"http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf [Accessed March 13, 2014]."},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.023_b0165","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jviromet.2010.11.024","article-title":"Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus","volume":"171","author":"Grund","year":"2011","journal-title":"J Virol Methods"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2019.06.023_b0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jviromet.2012.03.004","article-title":"Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine","volume":"182","author":"Cheng","year":"2012","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.06.023_b0175","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.vaccine.2012.03.010","article-title":"Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial","volume":"30","author":"Li","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.06.023_b0180","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4161\/hv.19521","article-title":"Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial","volume":"8","author":"Meng","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.06.023_b0185","first-page":"370","article-title":"Update on Enterovirus 71 infections: epidemiology, molecular epidemiology, and vaccine development","volume":"6","author":"Lin","year":"2018","journal-title":"J Infect Dis Ther"},{"issue":"7","key":"10.1016\/j.vaccine.2019.06.023_b0190","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00705-009-0413-x","article-title":"Seroprevalence and molecular epidemiology of enterovirus 71 in Germany","volume":"154","author":"Diedrich","year":"2009","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2019.06.023_b0195","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0264-410X(90)90083-X","article-title":"Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine","volume":"8","author":"Bahnemann","year":"1990","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2019.06.023_b0200","doi-asserted-by":"crossref","first-page":"e00038","DOI":"10.1128\/JVI.00038-17","article-title":"Beta-propiolactone inactivation of Coxsackievirus A16 induces structural alteration and surface modification of viral capsids","volume":"91","author":"Fan","year":"2017","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.023_b0205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01315592","article-title":"Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production","volume":"47","author":"Bahnemann","year":"1975","journal-title":"Arch Virol"},{"issue":"12\u201313","key":"10.1016\/j.vaccine.2019.06.023_b0210","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0264-410X(97)00051-0","article-title":"A candidate Ross River virus vaccine: preclinical evaluation","volume":"15","author":"Aaskov","year":"1997","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.023_b0215","first-page":"67","article-title":"Trials for preparation of inactivated sheep pox vaccine using binary ethyleneimine","volume":"10","author":"Awad","year":"2003","journal-title":"Egypt J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.023_b0220","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0264-410X(95)80011-2","article-title":"An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses","volume":"13","author":"Race","year":"1995","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2019.06.023_b0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jviromet.2005.09.005","article-title":"Production and characterization of monoclonal antibodies against binary ethylenimine inactivated Nipah virus","volume":"132","author":"Berhane","year":"2006","journal-title":"J Virol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2019.06.023_b0230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1051\/vetres\/2009046","article-title":"Development of an experimental inactivated PRRSV vaccine that induces virus-neutralizing antibodies","volume":"40","author":"Vanhee","year":"2009","journal-title":"Vet Res"},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.023_b0235","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/JCM.11.2.120-122.1980","article-title":"Rabies virus inactivation by binary ethylenimine: new method for inactivated vaccine production","volume":"11","author":"Larghi","year":"1980","journal-title":"J Clin Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2019.06.023_b0240","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1097\/INF.0000000000001242","article-title":"The epidemiology of hand, foot and mouth disease in Asia: a systematic review and analysis","volume":"35","author":"Koh","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2019.06.023_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph13090890","article-title":"The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development","volume":"13","author":"Chang","year":"2016","journal-title":"Int J Environ Res Public Health"},{"issue":"26","key":"10.1016\/j.vaccine.2019.06.023_b0250","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2011.04.010","article-title":"Identification and characterization of a cross-neutralization epitope of Enterovirus 71","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.023_b0255","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jviromet.2011.02.003","article-title":"Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates","volume":"173","author":"Chang","year":"2011","journal-title":"J Virol Methods"},{"issue":"24","key":"10.1016\/j.vaccine.2019.06.023_b0260","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.vaccine.2009.03.060","article-title":"Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007","volume":"27","author":"Mizuta","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2019.06.023_b0265","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1469-0691.2007.01745.x","article-title":"Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998\u20132005","volume":"13","author":"Kung","year":"2007","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.vaccine.2019.06.023_b0270","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.micinf.2007.06.002","article-title":"Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide","volume":"9","author":"Foo","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2019.06.023_b0275","article-title":"Immunological evaluation and comparison of different EV71 vaccine candidates","volume":"831282","author":"Chou","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2019.06.023_b0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079599","article-title":"The cross-neutralizing activity of enterovirus 71 sub-genotype c4 vaccines in healthy Chinese infants and children","volume":"8","author":"Mao","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T01:13:31Z","timestamp":1609982011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19307844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":56,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X19307844"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}